FluidSense Appoints John C. Baldwin, M.D., Dean of Dartmouth Medical School, to Board of Directors

Apr 23, 2001, 01:00 ET from FluidSense Corporation

    NEWBURYPORT, Mass., April 23 /PRNewswire Interactive News Release/ --
 FluidSense Corporation today announced the appointment of John C. Baldwin,
 M.D. to its Board of Directors.  Dr. Baldwin, a cardiothoracic and
 transplantation surgeon, is currently the Dean of Dartmouth Medical School and
 Vice President for Health Affairs at Dartmouth College.  Dr. Baldwin's
 illustrious career includes leadership positions at some of the most
 prestigious medical institutions in the country, including Stanford
 University, Yale University, Baylor College of Medicine, and Harvard
 University.
     "Dr. Baldwin is an extraordinarily accomplished physician with a broad
 range of experience in healthcare.  We are very fortunate to have him join our
 board and look forward to his contributions toward our continuing growth as an
 infusion-therapy-process-improvement company," said Diane Munson, President
 and Chief Executive Officer of FluidSense.  "His extensive clinical
 leadership, coupled with his economic and managed care expertise, will provide
 tremendous value to FluidSense as we deliver on our promise to enhance the
 safety and efficiency of the infusion therapy process."
      "I hope to be helpful to FluidSense as it seeks to improve patient care,
 facilitate nursing practice, offer more patient-friendly and reliable
 outpatient therapy, and, most importantly, reduce medication errors related to
 infusion therapy in a nationwide context," said Dr. Baldwin.
     In addition to FluidSense, Dr. Baldwin serves on a number of other boards,
 including the Board of Overseers of Harvard University, where he is currently
 Vice Chairman of its Executive Committee, along with several other Visiting
 and Standing Committees at Harvard.  He has held leadership positions in many
 professional societies, including serving as Governor of the American College
 of Surgeons and President of the International Society of Cardiothoracic
 Surgeons.
     The author of more than 300 scientific publications, Dr. Baldwin serves on
 the editorial boards of numerous medical and scientific journals, including
 The Journal of Thoracic and Cardiovascular Surgery, Transplantation and
 Transplantation Science.
     Dr. Baldwin earned a B.A. degree, summa cum laude, from Harvard
 University.  He received a Rhodes Scholarship and studied physiology at Oxford
 University.  Dr. Baldwin received his M.D. from Stanford University and
 completed his residency and internship at Massachusetts General Hospital.  He
 completed his specialty training in cardiothoracic and transplantation surgery
 at Stanford University.
 
     FluidSense, an infusion-therapy-process-improvement company, has developed
 a novel infusion pump and service program allowing for significant
 improvements in the safety, efficiency, and effectiveness of infusion therapy.
 The FluidSense Infusion Services Program is currently in use at hospitals
 across the United States.  Headquartered in Newburyport, MA, FluidSense
 currently employs more than 70 people.
 
     Editor's Note: This release is available on the FluidSense website at:
 www.fluidsense.com
 
      Contact:
      Sally McCraven
      FluidSense Corporation
      (877) 499-3900, x209
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X67507712
 
 

SOURCE FluidSense Corporation
    NEWBURYPORT, Mass., April 23 /PRNewswire Interactive News Release/ --
 FluidSense Corporation today announced the appointment of John C. Baldwin,
 M.D. to its Board of Directors.  Dr. Baldwin, a cardiothoracic and
 transplantation surgeon, is currently the Dean of Dartmouth Medical School and
 Vice President for Health Affairs at Dartmouth College.  Dr. Baldwin's
 illustrious career includes leadership positions at some of the most
 prestigious medical institutions in the country, including Stanford
 University, Yale University, Baylor College of Medicine, and Harvard
 University.
     "Dr. Baldwin is an extraordinarily accomplished physician with a broad
 range of experience in healthcare.  We are very fortunate to have him join our
 board and look forward to his contributions toward our continuing growth as an
 infusion-therapy-process-improvement company," said Diane Munson, President
 and Chief Executive Officer of FluidSense.  "His extensive clinical
 leadership, coupled with his economic and managed care expertise, will provide
 tremendous value to FluidSense as we deliver on our promise to enhance the
 safety and efficiency of the infusion therapy process."
      "I hope to be helpful to FluidSense as it seeks to improve patient care,
 facilitate nursing practice, offer more patient-friendly and reliable
 outpatient therapy, and, most importantly, reduce medication errors related to
 infusion therapy in a nationwide context," said Dr. Baldwin.
     In addition to FluidSense, Dr. Baldwin serves on a number of other boards,
 including the Board of Overseers of Harvard University, where he is currently
 Vice Chairman of its Executive Committee, along with several other Visiting
 and Standing Committees at Harvard.  He has held leadership positions in many
 professional societies, including serving as Governor of the American College
 of Surgeons and President of the International Society of Cardiothoracic
 Surgeons.
     The author of more than 300 scientific publications, Dr. Baldwin serves on
 the editorial boards of numerous medical and scientific journals, including
 The Journal of Thoracic and Cardiovascular Surgery, Transplantation and
 Transplantation Science.
     Dr. Baldwin earned a B.A. degree, summa cum laude, from Harvard
 University.  He received a Rhodes Scholarship and studied physiology at Oxford
 University.  Dr. Baldwin received his M.D. from Stanford University and
 completed his residency and internship at Massachusetts General Hospital.  He
 completed his specialty training in cardiothoracic and transplantation surgery
 at Stanford University.
 
     FluidSense, an infusion-therapy-process-improvement company, has developed
 a novel infusion pump and service program allowing for significant
 improvements in the safety, efficiency, and effectiveness of infusion therapy.
 The FluidSense Infusion Services Program is currently in use at hospitals
 across the United States.  Headquartered in Newburyport, MA, FluidSense
 currently employs more than 70 people.
 
     Editor's Note: This release is available on the FluidSense website at:
 www.fluidsense.com
 
      Contact:
      Sally McCraven
      FluidSense Corporation
      (877) 499-3900, x209
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X67507712
 
 SOURCE  FluidSense Corporation